Variant Pharmaceuticals Has a New Name - ZyVersa Therapeutics, Inc.
IC 100 is a monoclonal antibody that uniquely inhibits the adaptor ASC component of multiple inflammasomes, providing potential to treat a broad group of inflammatory disorders.
By inhibiting intracellular ASC, IC 100 prevents oligomerization and ASC Speck formation, thereby blocking initiation of the inflammatory cascade. Outside the cell, IC 100 binds to the ASC component of the ASC Speck, inhibiting perpetuation of the massive inflammatory response.
By inhibiting both intra- and extracellular inflammasome-mediated response, IC 100 is expected to more effectively reduce inflammation.
Preclinical data summarized below demonstrate that IC 100 blocks the inflammatory cascade, as reflected by inhibition of both caspase-1 and IL-β.
Data below demonstrate IC 100 has lower immunogenicity (9%) than many biologics used to treat inflammatory diseases, suggesting IC 100 has less potential for acquired drug resistance.
IC 100 has strong pre-clinical data related to multiple indications, as summarized below.